Goodwill and Other Intangible Assets

9 Months Ended

Mar. 28, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets [Text Block]

GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):



Reporting Segments:	Balance at June 28, 2014		Purchase accounting adjustments			Currency translation adjustment			Balance at March 28, 2015
Consumer Healthcare	$	1,406.3	$	(6.2	)	$	(12.7	)	$	1,387.4
Nutritionals	510.1		(1.0		)	—			509.1
Rx Pharmaceuticals	1,258.3		(4.7		)	(31.4		)	1,222.2
API	97.6		—			(13.1		)	84.5
Specialty Sciences	201.8		(1.1		)	—			200.7
Total goodwill	$	3,474.1	$	(13.0	)	$	(57.2	)	$	3,403.9

Intangible Assets

Other intangible assets and related accumulated amortization consisted of the following (in millions):



	March 28, 2015				June 28, 2014
	Gross		Accumulated Amortization		Gross		Accumulated Amortization
Amortizable intangibles:
Distribution and license agreements	$	6,029.4	$	424.3	$	6,027.3	$	192.1
Developed product technology/formulation and product rights	977.2		352.4		931.7		302.5
Customer relationships	364.9		111.1		372.0		97.5
Trade names and trademarks	47.1		11.1		47.8		5.6
Non-compete agreements	14.6		6.5		15.3		9.4
Total	$	7,433.2	$	905.4	$	7,394.1	$	607.1
Non-amortizable intangibles:
Trade names and trademarks	$	56.4	$	—	$	59.5	$	—
In-process research and development	7.0		—		10.2		—
Total	63.4		—		69.7		—
Total other intangible assets	$	7,496.6	$	905.4	$	7,463.8	$	607.1

Certain intangible assets are denominated in currencies other than the U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements.

The Company recorded amortization expense of $321.9 million and $181.1 million for the nine months ended March 28, 2015 and March 29, 2014, respectively. The increase in amortization expense was due primarily to the incremental amortization expense incurred on the amortizable intangible assets acquired as part of the Elan acquisition.

Impairment Testing

The Company has filed breach of contract litigation against a third party as it believes the third party has wrongfully enabled a competitor against the Company on a new product line in the animal health category. The Company moved for a preliminary injunction to prevent the third party from licensing or otherwise enabling the competitor from entering or staying on the over-the-counter market with a directly competing product. During the third quarter of fiscal 2015, the motion was denied. The Company had goodwill and intangible assets with a total net book value of $434.4 million as of March 28, 2015 attributable to its Animal Heath reporting unit. The Company also had a supply agreement with this third party that expired at the end of calendar year 2014 and has not been renewed.

The Company deemed the events described above to be indicators of potential impairment of its Animal Health reporting unit's intangible assets, which include goodwill, indefinite-lived intangible assets, and definite-lived intangible assets. The Company performed impairment testing for all of its Animal Health intangible assets as of March 28, 2015 and none were determined to be impaired. The Company will continue to monitor and assess its Animal Health intangible assets for potential impairment should further impairment indicators arise and at least annually as applicable.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details